Epigenomics Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Noel Doheny

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	13.5yrs
CEO ownership	n/a
Management average tenure	no data
Board average tenure	4.4yrs

Recent management updates

Recent updates

CEO

Noel Doheny

13.5yrs

Tenure

Dr. Noel Thomas Doheny has been the Chief Executive Officer of Epigenomics Inc. at Epigenomics AG since May 2011. Dr. Doheny manages all US activities and global business development and partnership develo...

Board Members

Name	Position	Tenure	Compensation	Ownership
Helge Lubenow	Chairman of the Supervisory Board	8.5yrs	€25.00k	no data
Alexander Link	Vice-chairman of Supervisory Board	4.4yrs	€25.00k	no data
Jochen Hummel	Member of Supervisory Board	less than a year	no data	no data

4.4yrs

Average Tenure

54yo

Average Age

Experienced Board: ECX's board of directors are considered experienced (4.4 years average tenure).

Epigenomics Management

Management criteria checks 1/4

Key information

Recent management updates

Epigenomics AG, Annual General Meeting, May 29, 2024

Epigenomics AG Announces Resignation of Andrew Lukowiak from the Company and the Executive Board Effective May 31, 2023

Epigenomics AG Announces Resignation of Jorge Garces as Executive Board Member Effective January 31, 2021

Recent updates

New major risk - Financial position

New major risk - Negative shareholders equity

New minor risk - Financial data availability

Epigenomics AG, Annual General Meeting, May 29, 2024

New Day Diagnostics, LLC acquired Substantially all of Assets of Epigenomics AG for $9.8 million.

Second quarter 2023 earnings released: €0.62 loss per share (vs €0.32 loss in 2Q 2022)

Now 29% undervalued

New Day Diagnostics, LLC entered into an asset purchase agreement to acquire Substantially all of Assets of Epigenomics AG.

Now 24% undervalued

Epigenomics Shares Surge on Talks to Sell Nearly All Assets for $11.5m

Price target increased by 9.1% to €6.00

First quarter 2023 earnings released: €1.31 loss per share (vs €0.67 loss in 1Q 2022)

Epigenomics AG Announces Resignation of Andrew Lukowiak from the Company and the Executive Board Effective May 31, 2023

Full year 2022 earnings released: €2.96 loss per share (vs €0.87 loss in FY 2021)

No longer forecast to breakeven

No longer forecast to breakeven

Third quarter 2022 earnings released

Epigenomics AG to Report Q3, 2023 Results on Nov 09, 2023

Epigenomics Ag Reaffirms Revenue Guidance for the Full Year 2022

Second quarter 2022 earnings released

Epigenomics AG Confirms Outlook for Fiscal Year 2022

Price target increased to €1.07

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Epigenomics AG Confirms Earnings Guidance for the Year 2022

Price target decreased to €0.95

No longer forecast to breakeven

No longer forecast to breakeven

Price target decreased to €0.95

Price target decreased to €1.14

New Horizon Health Limited (SEHK:6606) entered into an agreement to acquire certain non-essential biological samples from Epigenomics AG (XTRA:ECX) for $6.7 million.

Epigenomics AG Announces Earnings Guidance for the Year 2021

Epigenomics AG Provides Earnings Guidance for the Year 2021

New 90-day low: €2.19

New 90-day low: €2.27

Epigenomics AG Announces Resignation of Jorge Garces as Executive Board Member Effective January 31, 2021

Epigenomics Ag Announces the U.S. Centers for Medicare & Medicaid Services (CMS) Have Issued A Negative Reimbursement Decision in Connection with the National Coverage Determination (NCD) of Epi proColon, Epigenomics' Blood Test for Colorectal Cancer Screening

Epigenomics AG to Report Fiscal Year 2020 Results on Mar 25, 2021

Price target lowered to €23.73

CEO

Tenure

Board Members

Average Tenure

Average Age